• Revised FY25 Underlying NPAT guidance to $27.5m from previous $30-$31m
• Softer market and operating conditions in March-April 2025 across all geographic markets
• Monitoring impact of Brisbane incident on IVF patient registrations and treatments

Monash IVF Group Limited (ASX: MVF) has provided an update on its anticipated Underlying NPAT for the year ending 30 June 2025. The company now expects FY25 Underlying Group NPAT to be approximately $27.5m, compared to previously provided guidance of between $30.0m and $31.0m at the time of the release of the company's 1H25 results on 27 February 2025. The revised guidance reflects the company's assessment of softer market and operating conditions in March 2025 that worsened in April 2025 across all of the company's geographic markets. Operating conditions have improved in May 2025 but not sufficiently to offset the impact from the previous two months. The company continues to monitor key indicators and any implications that may arise from the Brisbane incident announced on 11 April 2025, including Queensland and Australian new IVF patient registrations, returning IVF patients for stimulated cycles and frozen embryo transfers, and transfer of medical records and human material to alternative IVF providers. These indicators are currently consistent with the performance levels observed in the months leading up to the announcement of the Brisbane incident. Monash IVF will release its FY25 results on 22 August 2025 and will keep the ASX informed of further information as required by its disclosure obligations.

Monash IVF now expects FY25 Underlying Group NPAT to be approximately $27.5m, compared to previously provided guidance of between $30.0m and $31.0m.